# Emactuzumab

Source: https://onco.cc/drugs/emactuzumab/  
OnCo record `emactuzumab` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Emactuzumab is an experimental monoclonal antibody from SynOx Therapeutics in phase 3 trials for tenosynovial giant cell tumour, aimed at CSF1R.

## Summary

Emactuzumab is a monoclonal antibody developed by SynOx Therapeutics and Hoffmann-La Roche. Its target is CSF1R (the sponsor names CSF-1R). The sponsor states: Emactuzumab is given as five intravenous infusions once every two weeks; a trial exclusion criterion (prior therapy targeting CSF-1 or CSF-1R) indicates it is a CSF-1R-directed antibody used to treat tenosynovial giant cell tumour by disrupting CSF-1/CSF-1R signalling. ClinicalTrials.gov describes the intervention as: Emactuzumab administered once every 2 weeks (q2w). It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT05417789 (Study of Emactuzumab for Tenosynovial Giant Cell Tumour (TGCT)) and NCT03768063 (A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study), in tenosynovial giant cell tumour. The largest, NCT03768063, plans to enrol 1000 participants with primary completion expected 2028-07-05. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: monoclonal antibody
- Mechanism: Emactuzumab is given as five intravenous infusions once every two weeks; a trial exclusion criterion (prior therapy targeting CSF-1 or CSF-1R) indicates it is a CSF-1R-directed antibody used to treat tenosynovial giant cell tumour by disrupting CSF-1/CSF-1R signalling.

## Sources

- ClinicalTrials.gov: trials of Emactuzumab: https://clinicaltrials.gov/search?intr=Emactuzumab

## Connected records

- cancers: [Tenosynovial giant cell tumour (TGCT)](https://onco.cc/cancers/tenosynovial-giant-cell-tumour/)
- targets: [CSF1R](https://onco.cc/targets/csf1r/)
- companies: [Roche / Genentech](https://onco.cc/companies/roche-genentech/)
- trials: [A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study](https://onco.cc/trials/nct03768063/), [Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)](https://onco.cc/trials/nct05417789/)

---
JSON: https://onco.cc/api/v1/entities/emactuzumab.json